Trial Profile
A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Human papillomavirus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FUTURE-II; LTFU
- Sponsors Merck Sharp & Dohme Corp.
- 03 Oct 2020 Results assessing levels of HPV16 antibodies were related to the levels of the cross-reactive antibodies in population-based cohorts (FUTURE-II and PATRICIA) published in the Journal of Infectious Diseases
- 21 Feb 2020 Planned End Date changed from 1 Jan 2019 to 3 Mar 2025.
- 21 Feb 2020 Status changed from completed to active, no longer recruiting.